ClinicalTrials.gg
CompletedNCT00165711Updated Feb 19, 2019

The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.

A Phase 4 interventional study of Mecobalamin in Dementia With Vitamin B12 Deficiency, sponsored by Eisai Co., Ltd.. Completed at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2019-02-19.

Sponsored by Eisai Co., Ltd. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Dementia by Eisai Co., Ltd. — none open to participants now, none under way, none of them phase 3. Dementia · Eisai Co., Ltd..

Started
2003
with 1 other
Phase 4
3 of 15
none open now
Registered
2nd of 15
by date

Among the 15 studies in Dementia by Eisai Co., Ltd., this one is one of 2 that started in 2003, is one of 3 in phase 4, and was the 2nd registered.

Dementia

2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.

Browse Dementia studies →

Open to participants now

None of the 15 studies in Dementia by Eisai Co., Ltd. is open now. The open studies under Dementia, anywhere →

Who these studies take

Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.

This study: 60 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Dementia by Eisai Co., Ltd. as a file.
02

Study summary

Patients who fit the inclusion criteria are admitted into the study. They are given 3 IV injection of MBL in the first week and one tablet three times a day for 16 weeks.

03

Conditions studied

  • Dementia With Vitamin B12 Deficiency
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Dementia
  • Serum B12 \< 200 pmol/l
  • Serum Homocysteine level > 11.0 micro mol/L

Exclusion criteria

Exclusion:

Significant communication problems

  • deafness, dysarthria, dysphasia etc.
  • unstable DM or hypertension
  • alcohol abuse
  • co-existing diseases which may affect cognition e.g. cognitive cardiac failure, respiratory failure
  • folate \< 10 g/dl
  • concentration \< 10g/d
  • abnormal thyroid function test or VDRL
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)

Interventions

06

What researchers measure

Primary outcomes

  1. Mattis dementia rating scale

Secondary outcomes

  1. Category fluency test

  2. Delirium rating scale

  3. CNPI

  4. MMSE

  5. Plasma homocysteine

  6. Plasma isoprostane

07

Study locations

1 site
  • Chinese University of Hong Kong
    Hong Kong, Hong Kong, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00165711
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Sep 14, 2005
Start date
Mar 2003
Last update
Feb 19, 2019

Study contacts

Romeo Chu
study director · Eisai Asia Regional Services Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mecobalamin

Start the discussion